Preclinical Imaging (IN-VIVO) Market 2019 Size, Business Research, Revenue, Growth Insights to 2023
Preclinical Imaging (in-vivo) Market Insights
The swift increase in the technological advancements in clinical organizations, pharmaceutical companies, and research and development activities in clinical research organization is thrusting the demand for preclinical imaging in the current time. It has also been observed that due to favorable aspects and optimum applications of preclinical imaging, the market of the same is booming year by year and is also expected to bring marvelous opportunities in the forecast period.
Preclinical Imaging (in-vivo) Market is likely to expand significantly at a CAGR of 6.3% by 2023. The market, in the past, gained a valuation of approximately USD 2.01 billion in 2017, which is projected to surge in the upcoming years, according to Market Research Future Reports.
Preclinical imaging is used for imagining of living animals specifically for research purposes. Such research is done for drug development and other reasons. This process tends to be very vital to observe changes in the organs, cell or tissues in animals according to environmental changes and more. Preclinical imaging caters to an essential study for animal anatomy. Different types of methods are used for preclinical imaging such as CT imaging, MRI imaging, PET/SPECT imaging, multimodal imaging, optical imaging, ultrasound imaging, and photoacoustic (PAT) imaging.
Preclinical Imaging (in-vivo) Market Players
Market Research Future Reports have included some of the best market leaders, who are listed as Bruker Corporation (US), MR Solutions (UK), PerkinElmer (US), Fujifilm Holdings Corporation (Japan), Milabs B.V. (The Netherlands), Mediso Ltd. (Hungary), Miltenyi Biotec GmbH (Germany), LI-COR, Inc. (US), Aspect Imaging (Israel), Trifoil Imaging (US)
Preclinical Imaging (in-vivo) Market Drivers & Trends
It has been observed that the preclinical imaging market has enormous growth potential which is expected to continue over the forecast period. With the help of technological advancements in preclinical imaging and the increasing adoption of molecular imaging technology especially for drug development, these are obtained to be fantastic factors that are expected to drive the preclinical imaging market in the upcoming years. Moreover, in recent time, several companies are into collaborations with the biotechnology and pharmaceutical companies to increase its clinical footprint globally. This is also one of the significant factors that are expected to drive the global preclinical imaging market over the forecast period.
On the other hand, the demand for preclinical imaging market is also fueled by technical innovation and funding, which is also observed to be driving the demand for preclinical imaging market over the forecast period. With that, globally several clinical research organizations (CROs), research institutes, biotechnology, and pharmaceuticals companies and others have contributed to the preclinical imaging market in positive ways. Such collaborations and contributions have led the market to open ways for opportunities in the future and to make the medical sector more valuable and intensifying. Several governments of countries across the globe have also contributed to the market growth by encouraging research activities and initiating enormous investments for the development of medicines. This factor is also expected to witness the market growth in the forecasted period.
Furthermore, the expansion of the cosmetic industry, life sciences, and other preclinical products are mainly contributing to the global preclinical imaging market to gain high value until the end of 2023.
On the flip side, the high cost of preclinical imaging systems and lack of awareness regarding preclinical imaging technology is observed to obstruct the growth of the preclinical imaging market over the in the upcoming years.
Preclinical Imaging (in-vivo) Market Segmentation
According to the reports published by MRFR, the global preclinical imaging market has been segmented into modality, reagent, and region.
By the segmentation of modality, preclinical imaging market comprises of optical imaging systems, nuclear imaging systems, micro-MRI, micro-ultrasound, micro-CT, photoacoustic imaging system, and magnetic particle imaging systems. Wherein, the optical imaging system segment is leading on account of the largest market share in it since 2017.
By the segmentation of reagent, this market segment includes preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. Wherein, preclinical optical imaging reagents segment is expected to lead by gaining the most significant share segment of the market since 2017.
Get More Information:- https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365
Preclinical Imaging (in-vivo) Market Regional Outlook
The preclinical imaging market segmented regionally into North America, Europe, Asia-Pacific, and the Middle East & Africa.
The American region is likely to lead in the global preclinical imaging market owing to the presence of well-established market players, ongoing technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches. These all are making the market more authentic and hence, expanding rapidly due to advanced treatments requirements.
Whereas, Europe is projected to hold the second largest position in the global preclinical imaging market attributing to the increased funding to support preclinical researches by several research institutes.
On the other side, the preclinical imaging market in Asia-Pacific region is also recorded to spur exponentially due to medical advancement in countries such as China, Japan, South Korea and more.
The Middle East & Africa observed to have the least share of the preclinical imaging market on a global level.